Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Financing Activities (2016 - 2025)

Rocket Pharmaceuticals' Cash from Financing Activities history spans 10 years, with the latest figure at -$67000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 138.07% year-over-year to -$67000.0; the TTM value through Dec 2025 reached $148000.0, down 99.92%, while the annual FY2025 figure was $148000.0, 99.92% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$67000.0 at Rocket Pharmaceuticals, down from $215000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $189.5 million in Q3 2023 and bottomed at -$67000.0 in Q3 2025.
  • The 5-year median for Cash from Financing Activities is $1.4 million (2024), against an average of $32.6 million.
  • The largest annual shift saw Cash from Financing Activities soared 46664.45% in 2024 before it tumbled 138.07% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.1 million in 2021, then soared by 9445.77% to $108.4 million in 2022, then tumbled by 99.64% to $391000.0 in 2023, then skyrocketed by 46664.45% to $182.8 million in 2024, then tumbled by 100.04% to -$67000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Cash from Financing Activities are -$67000.0 (Q3 2025), $215000.0 (Q2 2025), and $182.8 million (Q4 2024).